Investigational Drug Information for Elexacaftor
✉ Email this page to a colleague
What is the development status for investigational drug Elexacaftor?
Elexacaftor is an investigational drug.
There have been 25 clinical trials for Elexacaftor.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2021.
The most common disease conditions in clinical trials are Fibrosis, Cystic Fibrosis, and Gastrointestinal Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, Emory University, and Imperial College London.
There are twenty-five US patents protecting this investigational drug and four hundred and fifty-two international patents.
Summary for Elexacaftor
| US Patents | 25 |
| International Patents | 452 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2021-09-01) |
| Vendors | 30 |
Recent Clinical Trials for Elexacaftor
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis | Chiesi USA, Inc. | Phase 4 |
| Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis | University of North Carolina, Chapel Hill | Phase 4 |
Clinical Trial Summary for Elexacaftor
Top disease conditions for Elexacaftor
Top clinical trial sponsors for Elexacaftor
US Patents for Elexacaftor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Elexacaftor | ⤷ Try a Trial | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-- fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxa- mide | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Pharmaceutical composition and administrations thereof | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Modulators of cystic fibrosis transmembrane conductance regulator | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| Elexacaftor | ⤷ Try a Trial | Pharmaceutical compositions for treating cystic fibrosis | Vertex Pharmaceuticals Incorporated (Boston, MA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Elexacaftor
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Elexacaftor | Australia | AU2007235260 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | Brazil | BRPI0710965 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | Canada | CA2648719 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | Canada | CA2869945 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | China | CN101460489 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | China | CN103254177 | 2026-04-07 | ⤷ Try a Trial |
| Elexacaftor | Cyprus | CY1116979 | 2026-04-07 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
